Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California. Show more
Location: 280 East Grand Avenue, South San Francisco, CA, 94080, United States | Website: https://www.alumis.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
482.9M
52 Wk Range
$2.76 - $13.11
Previous Close
$4.64
Open
$4.64
Volume
663,129
Day Range
$4.61 - $4.80
Enterprise Value
31.25M
Cash
486.3M
Avg Qtr Burn
-86.31M
Insider Ownership
0.83%
Institutional Own.
81.06%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ESK-001 Details Moderate-to-severe plaque psoriasis | Phase 3 Data readout | |
ESK-001 Details Systemic lupus erythematosus | Phase 2b Data readout | |
A-005 Details Multiple sclerosis | Phase 2 Initiation |